Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Implications of the New Atrial Fibrillation Guideline

Implications of the New Atrial Fibrillation Guideline Letters guideline for atrial fibrillation (AF) treatment recommending Figure. Responses From Journal Editorials and Specialist Societies use of a refined stroke risk score and revised threshold for Regarding Evidence for Reversal of Practice oral anticoagulation (OAC) initiation. We assessed the Invited Commentary page 850 potential effect of this new Journal editorials 90 guideline by comparing the proportion of patients with AF rec- Specialist societies 1,2 ommended for OAC under the 2011 and 2014 guidelines. Methods | We used data from the Outcomes Registry for Bet- ter Informed Treatment of Atrial Fibrillation (ORBIT-AF) study, a national, prospective, outpatient registry of AF in patients 18 years or older at 176 sites in the United States. The primary outcome was the proportion of patients recom- mended for OAC at baseline under each guideline. The CHADS score, recommended for stroke risk assessment by the 2011 guideline, incorporates information on prior stroke Supports Neutral Challenges and transient ischemic attack, congestive heart failure and dysfunction, hypertension, age of 75 years or older, and dia- betes mellitus (score range, 0-6). The revised 2014 guideline recommends use of the CHA DS -VASc score, which 2 2 increases the point value from 1 to 2 for age of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Implications of the New Atrial Fibrillation Guideline

Fang, Margaret C.
JAMA Internal Medicine , Volume 175 (5) – May 1, 2015
Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/implications-of-the-new-atrial-fibrillation-guideline-k2hgew0ZZU
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2015.20
pmid
25730502
Publisher site
See Article on Publisher Site

Abstract

Letters guideline for atrial fibrillation (AF) treatment recommending Figure. Responses From Journal Editorials and Specialist Societies use of a refined stroke risk score and revised threshold for Regarding Evidence for Reversal of Practice oral anticoagulation (OAC) initiation. We assessed the Invited Commentary page 850 potential effect of this new Journal editorials 90 guideline by comparing the proportion of patients with AF rec- Specialist societies 1,2 ommended for OAC under the 2011 and 2014 guidelines. Methods | We used data from the Outcomes Registry for Bet- ter Informed Treatment of Atrial Fibrillation (ORBIT-AF) study, a national, prospective, outpatient registry of AF in patients 18 years or older at 176 sites in the United States. The primary outcome was the proportion of patients recom- mended for OAC at baseline under each guideline. The CHADS score, recommended for stroke risk assessment by the 2011 guideline, incorporates information on prior stroke Supports Neutral Challenges and transient ischemic attack, congestive heart failure and dysfunction, hypertension, age of 75 years or older, and dia- betes mellitus (score range, 0-6). The revised 2014 guideline recommends use of the CHA DS -VASc score, which 2 2 increases the point value from 1 to 2 for age of

Journal

JAMA Internal Medicine – American Medical Association

Published: May 1, 2015

References

  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
    January, CT; Wann, LS; Alpert, JS
  • Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation [published online March 2, 2015].
    O’Brien, EC; Kim, S; Hess, PL
  • Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008.
    Fang, MC; Coca Perraillon, M; Ghosh, K; Cutler, DM; Rosen, AB
  • Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.
    Eckman, MH; Singer, DE; Rosand, J; Greenberg, SM
  • The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
    Singer, DE; Chang, Y; Fang, MC
  • Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington, AR; Armstrong, EP; Nolan, PE; Malone, DC
  • Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
    Ogilvie, IM; Newton, N; Welner, SA; Cowell, W; Lip, GY